Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) EBITDA (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed EBITDA for 11 consecutive years, with -$92.6 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA fell 801.49% to -$92.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$130.3 million, a 68.19% decrease, with the full-year FY2025 number at -$130.3 million, down 68.19% from a year prior.
  • EBITDA was -$92.6 million for Q4 2025 at Cartesian Therapeutics, down from -$35.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $28.7 million in Q1 2022 to a low of -$177.6 million in Q4 2023.
  • A 5-year average of -$20.9 million and a median of -$10.8 million in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: tumbled 3128.85% in 2023, then surged 221.34% in 2024.
  • Cartesian Therapeutics' EBITDA stood at $12.2 million in 2021, then crashed by 52.05% to $5.9 million in 2022, then crashed by 3128.85% to -$177.6 million in 2023, then surged by 94.22% to -$10.3 million in 2024, then plummeted by 801.49% to -$92.6 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's EBITDA are -$92.6 million (Q4 2025), -$35.9 million (Q3 2025), and $15.9 million (Q2 2025).